its all about the surgibot, not the old 2010 spider, due to the fact that the spider is manual surgical system but with amazing flexible technology. Now that flexible technology is being transferred to a fully capable robotic surgical platform. selling for $500k it will be a no brainer for the 5,000 small private surgery centers and ~3,000 150 beds or less hospitals in the US that operate on such a tight budget. A $200k difference in price compared to SPORT system is a big deal for these small hospitals with tiny budgets. TRXC will be huge and the doctors are behind it. Google Dr. Gagner/Spider, he is a pioneer of minimally invasive surgery and has used the spider over 400 times Im not sure he would be wrong, look at his credentials, or check out Liu also an amazing world renowned surgeon. The guy who said it sucked is probably invested in TITXF and never actually used the SPIDER, given the fact that mayo and titan are connected, dont you sense a little bias?
And here's a piece of info that I may as well share, and just take it for what it is. I conducted a 1hr+ interview with mgmt of TRXC and mgmt of TITXF. When I asked TRXC, "What about TITXF, what do you think of their SPORT is it more advanced than TRXCs?" I received a polite reply along the lines of 'listen, we are aware of there developments and personally know the management over there (at least Todd Pope does) and we're not going to bash any company and we will let you judge, we will note that we do have significantly more employees working on this system around the clock (100+ employees vs ~12 at titan).
Now I asked Titan MGMT the same question, and they replied along the lines of, "listen, we know mgmt over from way back and like what they are doing, but our product offers so many benefits the 3d vision more advanced than TRXC's and our haptic feedback is very innovative and......." they sounded somewhat defensive and were just bashing. Just my two cents. Both companies are now fully funded to bring their product to commercialization, one a full year earlier than the other. TRXC has analyst coverage, now have 8 venture capitalists behind it, and will be selling a $500K system in less than a year. Its hard not to follow the smart money.
I purchased my core position of TRXC at around $0.60 when it was SafeStitch Medical, so Im still doing find and am in the green, as my .60 entry is actually $3.00 entry on split adjusted basis. Now this is the time ive been waiting for to finally add at steep discount.
Tick tock time will tell which turns out to be the better investment and fact that TRXC is on NYSE has analyst coverage tells me much farther ahead of the game. trading at discount right now
